The three COVID-19 vaccines authorized for use in the United States are not “well-matched” against the BA.2 virus subvariant, which has recently been estimated to have become dominant in the country, U.S. regulators said on April 6. “While currently available vaccines are not well-matched to the dominant circulating variant—which is the Omicron BA.2 sublineage—we do still have some residual vaccine effectiveness,” particularly against severe outcomes, Dr. Dorian Fink, an official with the Food and Drug Administration (FDA), said. Fink was speaking during a meeting with the FDA’s vaccine advisory panel, convened to discuss future actions to combat the COVID-19 pandemic. BA.2 has shown signs of better evading some COVID-19 treatments, prompting the FDA on Tuesday to yank emergency authorization for one of them, a monoclonal antibody called sotrovimab. But the regulator has resisted changing the emergency clearance for the COVID-19 vaccines so far, even as they continue to be less …